Clinical trial
Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides
NCT00445419 · Pevion Biotech Ltd, Industry · Completed
Key facts
| NCT number | NCT00445419 |
|---|---|
| Title | Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides |
| Official title | A Phase I Single-blind Randomised Placebo Controlled Dose Escalating Study of One Virosome Formulated CD4 and Two Virosomes Formulated CD8 Hepatitis C Virus (HCV) Vaccine Components (PEV2A and PEV2B) Administered to Healthy Adult Volunteers |
| Lead sponsor | Pevion Biotech Ltd, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Biological |
| Interventions | PEV2A PEV2B |
| Enrollment | 30 |
| Start date | Dec 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Mar 9, 2007 |
| Last update posted | Feb 8, 2010 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: